Skip to main content

Outlook Therapeutics, Inc.

OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649989

In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Outlook Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of OTLK: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders6370+7
Shares21.2M24.0M+2.80M (+13.2%)
Value$46.0M$32.6M−$13.4M (−29.2%)

New holders (14)

Institutions that held Outlook Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to OTLK in Q4 2021
InstitutionSharesValue% of portfolio
Gsa Capital Partners LLP210,042$286.0K0.04%
Marshall Wace, LLP153,565$209.0K0.00%
Envestnet Asset Management Inc36,461$50.0K0.00%
Terry L. Blaker34,044$46.0K0.00%
UBS Group AG31,889$43.0K0.00%
KWB Wealth27,284$37.0K0.01%
Alamar Capital Management, LLC20,000$27.0K0.02%
PVG Asset Management Corp13,225$18.0K0.07%
Transcend Wealth Collective, LLC10,000$14.0K0.00%
H. L. Ormond & Company, LLC10,000$13.0K0.02%
Aquatic Capital Management LLC9,100$12.0K0.02%
Gables Capital Management Inc.3,500$5.00K0.00%
Sargent Bickham Lagudis LLC1,000$1.00K0.00%
FMR LLC89$00.00%

Sold out (7)

Institutions that held Outlook Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of OTLK in Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
AXA S.A.145,013$315.0K
Walleye Capital LLC47,557$103.0K
Commonwealth Equity Services, LLC21,522$46.0K
Infrastructure Capital Advisors, LLC17,300$38.0K
Walleye Trading LLC15,071$33.0K
Squarepoint Ops LLC11,300$25.0K
Jacobi Capital Management LLC3,000$7.00K